Table 4.
Study | Raman et al. 12 | Wang et al. 13 | Koo et al. 17 | Diogenes et al. 18 | Jarjou et al. 19 | Ward et al. 22 | ||
Time point | Neonatal | Neonatal | Within the first week | 5 weeks | 2 weeks | 13 weeks | 52 weeks | 8–12 years |
Whole body |
BMD NS BMC NS BA NS |
BMD NS BMC NS BA NS |
BMD NS BMC NS BA NS |
BMD NS BMC NS BA NS |
BMD NS BMC NS b BA NS b |
BMC ↓ F/NS M ns F/NS M |
||
Lumbar spine |
BMD NS BMC NS BA NS |
BMC ↓ F/NS M NS F/NS M |
||||||
Total hip |
BMC ↓ F/NS M NS F/NS M |
|||||||
Midshaft radius/radius/ulna/tibia/fibula |
BMD ↑ a |
BMD ↑ |
BMD NS BMC NS BA NS |
BMD NS BMC NS BA NS |
BMD NS BMC NS BA NS |
NS, no significant differences between the study groups; ↑, significantly higher compared with the placebo, P ≤ 0.05; ↓, significantly lower compared with the placebo, P ≤ 0.05.
Considering both studied calcium supplementation groups (300 and 600 mg).
Significantly slower increase in BMC and BA between the age of 2 and 52 weeks in the calcium supplementation group.
In the study by Ward et al., 22 two models were constructed to test for sex*supplement effects on the growth of the children at 8–12 years. The first model included length at 52 weeks, current age, sex (M/F), maternal supplement group (Ca/P), and a sex*supplement group interaction.
In the study by Ward et al., 22 two models were constructed to test for sex*supplement effects on the growth of the children at 8–12 years. The second model was based on the first but adjusted the bone and body composition data for current body size, using height and weight for bone variables and height for lean and fat masses.
BA, bone area (cm2); BMC, bone mineral content (g); BMD, bone mass density (g/cm2); F, female; M, male; tot vBMD, total volumetric BMD (g/cm3).